No subcontract or supplier opportunities available

This contract involves the sole-source procurement of Breyanzi, a patient-specific CAR-T cell therapy that is delivered as a finished biopharmaceutical product with no modular components, ancillary services, or subcontracted elements. The entire manufacturing and delivery process is handled turnkey by the prime contractor, meaning no third-party suppliers or subcontractors are involved or permitted at any stage of production or fulfillment. The product is customized for individual patients and requires specialized, end-to-end control throughout its lifecycle, which justifies the exclusive nature of the procurement. The contract is issued under the Department of Veterans Affairs, specifically through the 262-NETWORK Contract Office 22 (36C262), with no set-aside classification or NAICS code assigned. There are no solicitation details, point of contact, or specific place of performance listed, and no opportunities exist for subcontractors or suppliers to participate. All activities related to the development, production, and delivery of Breyanzi are fully contained within the prime contractor’s operations, ensuring strict adherence to patient-specific protocols and regulatory requirements without external involvement.